Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Continuous Manufacturing On Horizon As Competitive Edge In OTC Space

This article was originally published in The Pink Sheet Daily

Executive Summary

While OTC firms’ slimmer profit margins make equipment changes or other capital investments more difficult than for Rx firms, continuous manufacturing will be worth the investment, says CDER Director Janet Woodcock. “We’re going to see a lot of these out there,” she says.

You may also be interested in...



In Rare Cannabinoids, BioMedican Sees Alphabet Of Potential Dietary And Drug Ingredients

BioMedican is ready to produce CBG, cannabigerol, and THC-V, tetrahydrocannabivarin, through biosynthesis and plans by the end of the year to start making CBN, cannabinol, and THC-A, tetrahydrocannabinolic-acid.

‘Pharmaceutical’ Controls, Lower Costs: Future Of Cannabinoid Ingredients In Biosynthesis?

Synthetics are necessary for drugs containing cannabinoids because the active ingredient must be consistent from dose to dose. Cannabinoids extracted from hemp vary from plant to plant and more widely from crop to crop, but consistency should matter for cannabinoids used as dietary ingredients, says BioMedican president Dennis O’Neill.

US FDA’s 30-Day Extension For Nitrosamine Assessments Short Of Industry Recommendation

Revision to FDA's September 2020 guidance on assessing nitrosamine impurity risks associated with all chemically synthesized APIs and all approved drug products that contain those APIs doesn’t satisfy industry stakeholders.

Topics

UsernamePublicRestriction

Register

IV001392

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel